Sponsored by the Academy for Continued Healthcare Learning
This activity is supported by an educational grant from Neurocrine BioSciences.
This Clinical Commentary consists of an HD video roundtable discussion with two leading expert psychiatrists in the field, who participate in a panel discussion of tardive dyskinesia (TD) as a widespread and undertreated condition in psychiatric populations, as well as the importance of evidence-based differential diagnostics, newly approved therapeutics for treatment of the condition, and strategies for both personalized and improved patient care. This activity additionally includes an interview with a leading neurologist who reviews diagnostic algorithms for TD and shares her perspective on the impact of new drug approvals and strategies for working together with psychiatrists in managing patients with TD. Throughout the activity, testimonials of a patient with tardive dyskinesia are incorporated to bring relevance to the patient perspective, experience and treatment goals.
This activity is intended for psychiatrists, neurologists, and other clinicians involved in the management of patients with TD.
Upon completion of this activity, participants will be able to:
Evaluate possible clinical indication(s) and patient population(s) that may be at increased risk for tardive dyskinesia (TD)
Discuss the role of dopamine antagonists and/or other therapies that may play a role in the pathophysiology of TD
Recognize the risks, benefits, and possible complications associated with managing TD in the psychiatric population
Describe the importance of differential diagnosis and current evidence-based treatment paradigms for patients at risk for TD
Interpret the clinical trial efficacy and safety data of novel and emerging therapies for TD
Conflict Of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
Cynthia Comella, MD Professor, Department of Neurological Sciences Section of Parkinson’s Disease and Movement Disorders Rush University Medical Center Chicago, IL
Dr. Comella discloses the following: Review Panel: Neurocrine Biosciences
Christoph Correll, MD Professor, Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research Professor, Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine Medical Director, Recognition and Prevention, Department of Psychiatry, The Zucker Hillside Hospital New York, NY
Dr. Correll discloses the following: Consultant/Advisor: Alkermes, Allergan, Angelini, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medavante, Merck, Neurocrine Biosciences, Otsuka, Pfizer, ROVI, Servier, Sunovion, Takeda, and Teva Grant Support: Janssen and Teva Shareholder: LB Pharma Royalties: UpToDate
John Kane, MD Professor & Chairman, Psychiatry, Neurology and Neurosciences Donald & Barbara Zucker School of Medicine at Hofstra/Northwell Chairman, Department of Psychiatry The Zucker Hillside Hospital New York, NY
Dr. Kane discloses the following: Consultant/Advisor: Alkermes, Allergan, Eli Lilly, Forum, Genentech, Lundbeck, Intracellular Therapies, Merck, Janssen, Johnson & Johnson, Neurocrine Biosciences, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, and Teva Pharmaceuticals Grant Support: Otsuka, Lundbeck, and Janssen Shareholder: LB Pharma and Vanguard Research Group
Brian, a Tardive Dyskinesia patient for 20+ years New York, NY
Patient Disclosure: No financial relationships reported
Accredited Provider Disclosures
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Tetrabenazine, Clonazepam and Vitamin E for the management of tardive dyskinesia
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
To obtain credit, a score of 75% on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact: Katlyn Cooper email@example.com